Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: implications for glucose metabolism improvements in type 2 diabetes

Simple item page
dc.contributor.authorChowdhury, M.K.H.
dc.contributor.authorTurner, N.
dc.contributor.authorBentley, N.L.
dc.contributor.authorDas, A.
dc.contributor.authorWu, L.E.
dc.contributor.authorRichani, D.
dc.contributor.authorBustamante, S.
dc.contributor.authorGilchrist, R.B.
dc.contributor.authorMorris, M.J.
dc.contributor.authorShepherd, P.R.
dc.contributor.authorSmith, G.C.
dc.date.issued2017
dc.description.abstractType 2 diabetes (T2D) is a global pandemic. Currently, the drugs used to treat T2D improve hyperglycemic symptom of the disease but the underlying mechanism causing the high blood glucose levels have not been fully resolved. Recently published data showed that salt form of niclosamide improved glucose metabolism in high fat fed mice via mitochondrial uncoupling. However, based on our previous work we hypothesised that niclosamide might also improve glucose metabolism via inhibition of the glucagon signalling in liver in vivo. In this study, mice were fed either a chow or high fat diet containing two different formulations of niclosamide (niclosamide ethanolamine salt - NENS or niclosamide - Nic) for 10 weeks. We identified both forms of niclosamide significantly improved whole body glucose metabolism without altering total body weight or body composition, energy expenditure or insulin secretion or sensitivity. Our study provides evidence that inhibition of the glucagon signalling pathway contributes to the beneficial effects of niclosamide (NENS or Nic) on whole body glucose metabolism. In conclusion, our results suggest that the niclosamide could be a useful adjunctive therapeutic strategy to treat T2D, as hepatic glucose output is elevated in people with T2D and current drugs do not redress this adequately.
dc.description.statementofresponsibilityMd. Kamrul Hasan Chowdhury, Nigel Turner, Nicholas L. Bentley, Abhirup Das, Lindsay E. Wu, Dulama Richani, Sonia Bustamante, Robert B. Gilchrist, Margaret J. Morris, Peter R. Shepherd, Greg C. Smith
dc.identifier.citationScientific Reports, 2017; 7(1):40159-1-40159-9
dc.identifier.doi10.1038/srep40159
dc.identifier.issn2045-2322
dc.identifier.issn2045-2322
dc.identifier.orcidGilchrist, R.B. [0000-0003-1611-7142]
dc.identifier.urihttp://hdl.handle.net/2440/120960
dc.language.isoen
dc.publisherSpringer Nature
dc.relation.grantARC
dc.rights© The Author(s) 2017. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
dc.source.urihttps://doi.org/10.1038/srep40159
dc.subjectGlucose metabolism; type 2 diabetes
dc.titleNiclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: implications for glucose metabolism improvements in type 2 diabetes
dc.typeJournal article
pubs.publication-statusPublished

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
hdl_120960.pdf
Size:
1.33 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download

Collections

Medicine publications